Prostate Cancer
Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers.
January 22, 2024
Palliative urologic surgery for metastatic prostate cancer: what needs to be considered in the future?.
January 22, 2024
DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2.
January 22, 2024
Impact of curative radiotherapy on the immune status of patients with localized prostate cancer.
January 22, 2024
Stereotactic Ablative Radiation Therapy in 3 Fractions Induces a Favorable Systemic Immune Cell Profiling in Prostate Cancer Patients.
January 22, 2024
Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
January 19, 2024
Exploiting the DNA Damage Response for Prostate Cancer Therapy.
January 19, 2024
Lymphovascular Invasion at the Time of Radical Prostatectomy Adversely Impacts Oncological Outcomes.
January 19, 2024
225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings.
January 19, 2024
De-Escalation of Therapy for Prostate Cancer.
January 18, 2024